Journal
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Volume 35, Issue 3, Pages 164-178Publisher
HUMANA PRESS INC
DOI: 10.1007/s12016-008-8080-3
Keywords
Cystic fibrosis; Gene therapy; AAV; Ad; Non-viral; Liposomes; CF; Immune responses
Categories
Funding
- NCATS NIH HHS [UL1 TR000161] Funding Source: Medline
- NHLBI NIH HHS [P01 HL051811] Funding Source: Medline
Ask authors/readers for more resources
Cystic Fibrosis (CF) is an autosomal recessive disorder due to mutations in the CF transmembrane conductance regulator (CFTR) gene that lead to defective ion transport in the conducting pulmonary airways and exocrine glands. Through a process that is not fully understood, CFTR defects predispose affected patients to chronic endobronchial infections with organisms such as Pseudomonas aeruginosa and Staphylococcus aureus. Following the discovery of the CFTR gene in 1989, CF became one of the primary targets for gene therapy research. Early enthusiasm surrounded the new field of gene therapy during most of the 1990s and it led academics and clinicians on a big effort to apply gene therapy for cystic fibrosis. Clinical studies have been pursued using recombinant adenovirus, recombinant adeno-associated virus, cationic liposomes, and cationic polymer vectors. Although to this date no dramatic therapeutic benefits have been observed, a lot of information has been gained from the pre-clinical and clinical studies that were performed. This learning curve has led to the optimization of vector technology and an appreciation of immune and mechanical barriers that have to be overcome for successful delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available